Skip to main content
. 2017 Jun 15;35(8):831–844. doi: 10.1007/s40273-017-0527-z

Fig. 5.

Fig. 5

One-way sensitivity analysis: tornado diagram for the incremental cost-effectiveness ratio (per quality-adjusted life-year) of pembrolizumab vs. standard-of-care. AE adverse event, ICER incremental cost-effectiveness ratio, KM Kaplan–Meier, OS overall survival, PFS progression-free survival, SoC standard of care, ToT time on treatment